Issues Archive

The most complete archive of clinical and pathology lab industry news available, including issues from 1997 to the present.

Volume XXVI No. 2 – February 4, 2019

In this issue:

NOW THAT MOST HOSPITALS ARE INCLUDED as applicable laboratories that must report their PAMA private payer lab test price data to the Centers for Medicare and Medicaid Services, managers of those labs will benefit from the incisive analysis in this issue of the lessons learned during the 2017 PAMA reporting cycle. THE DARK REPORT further offers recommendations on how labs can do a better job of gathering and reporting their own data to CMS. Also, TDR delivers an exclusive analysis of why the Government Accounting Office’s assertion that CMS will be paying billions more for Part B clinical lab tests is simply wrong.

View Issue TOC

Volume XXVI No. 1 – January 14, 2019

In this issue:

LAB ADMINISTRATORS AND PATHOLOGISTS should pay close attention to emerging new disruptive forces outlined in this issue — and their potential to upend the clinical laboratory industry as it exists today. From slashed Medicare prices, to the risk of $10,000-per-day penalties for PAMA price-reporting errors, to narrowing networks, 2019 will be one of the most challenging years facing the clinical lab industry since the early 1990s. At the same time, THE DARK REPORT details five specific strategies from a highly-respected lab industry executive that administrators can leverage to survive and thrive in the storm.

View Issue TOC

Volume XXV No. 18 – December 24, 2018

In this issue:

THE NEW YEAR will be a challenging one for clinical labs and pathology groups, based on significant events of the last year. For one: If your hospital is marked under the PAMA law as having “applicable” labs, you’ll be struggling to comply with reporting private payer lab price data. Meanwhile, all labs will face tougher anti-fraud rules, and common pass-through billing practices may prompt private payers to sue. These issues and more are reviewed in this issue, including expert guidance for lab managers on navigating the various minefields.

View Issue TOC

Volume XXV No. 17 – December 3, 2018

In this issue:

DID CONGRESS JUST PASS A LAW that makes innocent labs guilty of criminal acts? At the last minute, Congress added all clinical laboratories to a far-reaching anti-kickback provision in the newly-enacted Support for Patients and Communities Act — a provision that makes common practices such as paying commissions to sales staff or placing phlebotomists in labs could be illegal. Worse: The experts are baffled by the language of the new law. Notes one of these experts in this issue, “Someone in the clinical lab industry may have to get prosecuted before we get some clarity, unless the Secretary of HHS issues clarifying regulations.”

View Issue TOC

Volume XXV No. 16 – November 13, 2018

In this issue:

THE DARK REPORT ANALYZES a change of heart by the federal Centers for Medicare and Medicaid Services in the way it will collect data about the lab test prices paid by private health insurers. Good news? Not so fast. The changes CMS calls for won’t impact the Medicare fee schedule for two years. But on Jan. 1, 2019, CMS will make another painful 10% cut in what it pays for lab tests. Also in this issue is an exclusive look at how an innovative commercial lab company is developing ways to collaborate with physicians, health insurers, ACOs and others to improve patient care and lower the cost of care—and be paid for those contributions.

View Issue TOC

Volume XXV No. 15 – October 22, 2018

In this issue:

WHO WILL BE NEXT? As federal prosecutors indicate in court there’s more to come in the ongoing Theranos investigation, that leaves the lab industry wondering who else might be charged with crimes. Reported only in THE DARK REPORT, this development means that any number of people could be targeted: former members of the Board of Directors, various consultants, even vendors. Meanwhile, Medicare has begun publicly posting prices charged by every pathologist in the country — so that every one of them can find out what their competition is up to. Will a new price war result? THE DARK REPORT offers a pricing “sweet spot” for readers to consider.

View Issue TOC

Volume XXV No. 14 – October 1, 2018

In this issue:

TWO FEDERAL COURT RULINGS that will have immediate impact on the clinical lab industry are analyzed in detail in this issue. In a major setback for the ACLA lawsuit against the federal Department of Health and Human Services, a judge has ruled that the court lacks jurisdiction to take the case. THE DARK REPORT also offers an exclusive interview with the ACLA’s lead attorney to help readers understand the issues surrounding a possible appeal. Also exclusive to THE DARK REPORT is a report about a court ruling that two fairly common lab business practices are illegal inducements.

View Issue TOC

Volume XXV No. 13 – September 10, 2018

In this issue:

CLINICAL LABORATORY MANAGERS will learn in this issue about two trends that are driving a movement to standardize laboratory operations across large regions: the integration of clinical care and the need for hospitals and health networks to improve patient outcomes continuously. THE DARK REPORT dives deeply into the details of an ambitious program along these lines in Michigan. Also, Theranos’ dying breath is detailed as the once-vaunted company finally goes under.

View Issue TOC

Volume XXV No. 12 – August 20, 2018

In this issue:

THE DARK REPORT HAS UNCOVERED a previously unnoticed trend that turns common wisdom on Wall Street upside down: Hospitals and health systems may be taking back control of their their laboratory outreach programs instead of selling them, and committing major resources to their inpatient labs instead of outsourcing their management. TDR is the first to analyze this trend in three separate articles. Also, for both anatomical and clinical pathology, value-based payment is coming, creating an opening for pathologists who move quickly.

View Issue TOC

Volume XXV No. 11 – July 30, 2018

In this issue:

THE DARK REPORT DEMONSTRATES that CMS is once again seemingly ignoring Congress’ intent with the Protecting Access to Medicare Act (PAMA) by leaving out hospital labs and outreach laboratories from price reporting. What will the outcome be this time around? Also, only TDR has detected a potential opportunity in managed care contracting for regional and outreach labs that can demonstrate how they add value to patient care.

View Issue TOC

Don’t Be at the Mercy of the Tumultuous Healthcare Revolution

Subscribe to The Dark Report for as little as $15.27 per week.

Get the most expert business intelligence for clinical laboratories and pathology groups available today. Subscribe to The Dark Report.

Get digital and print editions of The Dark Report for only $22.97 per week. Plus a Free bonus Executive Briefing

Get web access of The Dark Report for only $19.12 per week. Plus a Free bonus Executive Briefing

Get a hard copy of The Dark Report delivered to your home for only $15.27 per week. Plus a Free bonus Executive Briefing

View our privacy policy

Volume XXVI No. 2 – February 4, 2019

NOW THAT MOST HOSPITALS ARE INCLUDED as applicable laboratories that must report their PAMA private payer lab test price data to the Centers for Medicare and Medicaid Services, managers of those labs will benefit from the incisive analysis in this issue of the lessons learned during the 2017 PAMA reporting cycle. THE DARK REPORT further offers recommendations on how labs can do a better job of gathering and reporting their own data to CMS. Also, TDR delivers an exclusive analysis of why the Government Accounting Office's assertion that CMS will be paying billions more for Part B clinical lab tests is simply wrong.

See the full table of contents

Issues Archive

In this issue:

In this issue:

In this issue:

In this issue:

In this issue:

In this issue:

In this issue:

In this issue:

In this issue:

In this issue:

Enter Your Login Credentials